Proteostasis Therapeutics Inc., a Cambridge, Mass.-based developer of small molecule therapeutics to control the body's protein homeostasis,, has raised $45 million in Series A funding. Backers include HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures.
PRESS RELEASE
Proteostasis Therapeutics, Inc. (PTI) today announced that it has secured $45 million in a Series A financing to develop Proteostasis Regulator
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.